RxDoctor Payments Data

Matthew Tellman, MD

Urology · Fishers, INNPI 1992187371

Payments from drug & device makers

What this record shows

This record is dominated by other: $22,071 of the $26,239 with a category attached, or 84.1%. Central Indiana URS Consumables, LLC accounts for 84.1% of it on its own, with 44 other manufacturers making up the rest.

$26,239in general payments, 2019–2025

Across 183 payments — averaging $143.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Central Indiana URS Consumables, LLC$22K
  • AbbVie$696
  • Sumitomo Pharma America, Inc.$631
  • Boston Scientific$342
  • Tolmar, Inc.$247
  • Urogen Pharma, Inc.$178
  • plus $2K from 39 others
$15,600in ownership & investment interests, 2019–2025

Across 2 payments — averaging $7800.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • Central Indiana URS Consumables, LLC$16K

What the payments were for

  • Food & beverage$4,13316%
  • Education$350%
  • Other$22,07184%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,239 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$183,301
Medicare patients
603
Services billed
2,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron168$171,825
MyrbetriqMirabegron113$102,371
Tamsulosin Hcl533$7,796
Estradiol51$3,407
Silodosin25$2,349
Finasteride186$2,029
Alfuzosin Hcl ErAlfuzosin Hcl80$1,435
Oxybutynin Chloride ErOxybutynin Chloride50$1,363
Trospium Chloride12$1,286
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst88$1,100
Potassium Citrate ErPotassium Citrate14$916
Dutasteride16$633
Cephalexin86$430
Oxybutynin Chloride24$282
Ciprofloxacin Hcl30$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$631$171,825168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.

Other urology in Fishers

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →